百济神州(06160)发布公告，于2025年12月31日，董事会及或董事会薪酬委员会根据2016期权及激励计 划的条款授予155名承授人合共5.33万股美国存托股份受限制股份单位。该等受限制股份单位相当于 69.32万股股份，约占本公告之日公司发行股份总数的0.04%。追加内容 本文作者可以追加内容哦 ! 百济神州(06160)发布公告，于2025年12月31日，董事会及或董事会薪酬委员会根据2016期权及激励计 划的条款授予155名承授人合共5.33万股美国存托股份受限制股份单位。该等受限制股份单位相当于 69.32万股股份，约占本公告之日公司发行股份总数的0.04%。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司 (根據瑞士法律註冊成立的公司) | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | 請見備注 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | 本月底法定/註冊股本總額： USD 231,1 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年12月31 日，董事會及╱或董事會薪酬委員會根據2016期權及激勵計劃的條款向一百五十 五名承授人授出涉及合共53,322股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的受限制股份單位 於2025年12月31日，董事會及╱或董事會薪酬委員會根據2016期權及激勵計劃 的條款授予一百五十五名承授人合共53,322股美國存託股份受限制股份單位。該 等受限制股份單位相當於693,186股股份，約佔本公告之日公司發行股份總數的 0.04%。 授出受限制股份單位詳情 受限制股份單位詳情如下： 1 受限制股份單位總數 （美國存託股份）: 因已授出受限制股份單位 獲歸屬而可予獲得的 新美 ...

Core Viewpoint - BeiGene's stock price increased nearly 3% in pre-market trading following the announcement of conditional approval for its self-developed BCL2 inhibitor, SOTYKTU (sotatercept), by the National Medical Products Administration (NMPA) for specific cancer treatments [1] Group 1: Drug Approval and Market Impact - BeiGene announced that its BCL2 inhibitor, SOTYKTU, received conditional approval from the NMPA for treating adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received at least one systemic treatment including a BTK inhibitor [1] - The approval also covers adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have undergone at least two systemic treatments, including a BTK inhibitor, making SOTYKTU the first and only BCL2 inhibitor approved for MCL treatment in China [1] - Following the news, BeiGene's stock price rose to $329.5 in pre-market trading, reflecting a 2.86% increase [2] Group 2: Stock Performance Metrics - The closing price of BeiGene's stock was $320.00, with a pre-market price of $329.50, indicating a significant upward movement [2] - The stock's trading volume was 293,100 shares, with a market capitalization of approximately $37.966 billion [2] - The stock has a 52-week high of $385.22 and a low of $174.74, showcasing its volatility in the market [2]

FF301 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | 請見備注 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | 本月底法定/註冊股本總額： USD 231,146.38 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人 ...

Core Viewpoint - BeiGene (06160.HK) announced the grant of a total of 53,322 restricted stock units to 155 participants under the 2016 option and incentive plan, equivalent to 693,186 shares, representing approximately 0.04% of the company's total issued shares as of the announcement date [1] Summary by Category - **Company Actions** - The board and/or the remuneration committee granted 53,322 restricted stock units to 155 participants [1] - The restricted stock units correspond to 693,186 shares [1] - **Shareholder Impact** - The granted shares represent about 0.04% of the total issued shares of the company as of the announcement date [1]

智通财经APP讯，百济神州(06160)发布公告，于2025年12月31日，董事会及╱或董事会薪酬委员会根据 2016期权及激励计划的条款授予155名承授人合共5.33万股美国存托股份受限制股份单位。该等受限制 股份单位相当于69.32万股股份，约占本公告之日公司发行股份总数的0.04%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年12月31 日，董事會及╱或董事會薪酬委員會根據2016期權及激勵計劃的條款向一百五十 五名承授人授出涉及合共53,322股美國存託股份的受限制股份單位。 受限制股份單位詳情如下： 授出日期： 2025年12月31日 2016期權及激勵計劃項下的受限制股份單位 承授人數目： 一百五十五名（包括一名服務提供者，其根據聘任就 本集團主要業務有關或附屬領域向本集團提供科學 諮詢服務，以幫助維持或提高本集團的競爭力） 於2025年12月31日，董事會及╱或董事會薪酬委員會根據2016期權及激勵計劃 的條款授予一百五十五名承授人合共53,322股美國存託股份受限制股份單位。該 等受限制股份單位相當 ...

Group 1 - The core point of the news is that BeiGene's new BCL2 inhibitor, SOTUCLAR (百悦达®), has received conditional approval from the National Medical Products Administration (NMPA) in China for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have previously received at least one systemic therapy including a BTK inhibitor, as well as for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two systemic therapies including a BTK inhibitor [1][2] - SOTUCLAR is the first of its kind to be approved in China, allowing Chinese patients to benefit from this innovative therapy ahead of other markets [1] - The approval process in China took only 8 months from acceptance to approval, highlighting the urgent treatment needs of patients with blood cancers who have developed resistance [2] Group 2 - The approval of SOTUCLAR marks a significant milestone in BeiGene's hematology product pipeline and reinforces the company's leadership in the treatment of B-cell malignancies [2] - SOTUCLAR has also received breakthrough therapy designation and priority review qualification from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory MCL who have received BTK inhibitors, potentially making it the first BCL2 inhibitor approved for this indication in the U.S. [1]

Group 1 - The A-share market experienced narrow fluctuations on January 7, with coal, chips, and innovative drug sectors leading in gains. The Southern Innovative Drug ETF (159858.SZ) rose by 1.60%, and Baijie Shenzhou increased by 3.29% [1] - The Chinese innovative drug industry is expected to undergo a value return and structural reshaping by 2025, with a shift in core logic towards product strength, platform capability, and global operational ability [1] - Policies are transitioning from encouraging innovation to a new phase of systematic and precise guidance, providing institutional support for original innovation [1] Group 2 - Capital is concentrating on companies with core technology platforms, clear clinical value, and global potential, favoring mid-to-late-stage projects in areas such as ADC, bispecific antibodies, CGT, and AI drug development [1] - The transaction amount for innovative drugs going overseas has reached a historical high, with deepening collaboration models [1] - Domestic ADC and bispecific antibody products have been approved and show globally leading data, while breakthroughs have been made in small molecule drugs targeting "undruggable" targets, and significant progress has been observed in cell therapies and nucleic acid drugs [1] Group 3 - The industry is transitioning from following innovation to original innovation, and from technology input to systematic output [1] - The trend for the innovative drug industry is positive, with strengthened global competitiveness, ongoing international expansion, and gradual realization of commercial profitability [1] - The medical device industry is experiencing a calming of influencing factors, with accelerated innovation and internationalization [1] Group 4 - The innovative drug industry is showing enhanced innovation vitality and significant internationalization results, with sufficient long-term development momentum [1] - The Southern Innovative Drug ETF (159858.SZ) can focus on innovative drugs and the industry chain, sharing the growth dividends of truly competitive companies amid industry differentiation and seizing opportunities for value reshaping [1]